Clinical progress of nanomedicine-based RNA therapies
The clinical application of nanoparticles (NPs) to deliver RNA for therapy has progressed rapidly since the FDA approval of Onpattro® in 2018 for the treatment of polyneuropathy associated with hereditary transthyretin amyloidosis. The emergency use authorization or approval and widespread global us...
| Published in: | Bioactive Materials |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co., Ltd.
2022-06-01
|
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452199X21004825 |